A robot could become the 'weapon' of choice for detecting and treating the most common cancer in men improving results and reducing side effects.

University of California Los Angeles Health Sciences UCLA researchers have discovered a common process in the development of latestage small cell cancers of the prostate and lung. These shared molecular mechanisms could lead to the development of drugs to...

SummaryMicropos Medical AB Micropos Medical is a medical device company. The company develops technologies that enhance the precision in radiotherapy of cancer including hypofractionation and stereotactic radio surgery SRS and stereotactic body radiotherap...

Randy F. Sweis discusses recent progress and next steps in the prostate cancer paradigm.

BOULDER Colo.&8211;BUSINESS WIRE&8211;Clovis Oncology Inc.ÂNASDAQ CLVS announced today that theÂU.S. Food and Drug AdministrationÂFDA has granted Breakthrough Therapy designation for RubracaÂÂrucaparib as a monotherapy treatment of adult patients w...

Its typical to think about cancer in terms of specific tissue types or organs in which cancers can form; like leukemia breast brain or prostate. Cancer researcher Tobias Janowitz M.D. Ph.D. takes a different approach; one that looks at cancer as a systemic...

But the notable survival advantage seen with primary treatment consisting of radical prostatectomy plus radiotherapy also came with a high cost to quality of life. Medscape Medical News

Harpoon Therapeutics Inc. a clinicalstage immunotherapy company developing a new class of T cell engaging therapeutics announced today that it has appointed Natalie R. Sacks M.D. as Chief Medical Officer. We are thrilled to w...

Clovis Oncologys Rubraca rucaparib has been designated as a Breakthrough Therapy by the FDA in prostate cancer paving the way for a faster review if clinical trials work out.The FDA has said that phase 2 data suggest the drug could represent ...

$CLVS to Highlight Results from Rubraca® rucaparib TRITON Prostate Program at ESMO18 Congress httpss22.q4cdn.com778348918filesdocnewsClovisOncologytoHighlightResultsfromRubracarucaparibTRITONProstateProgramatESMO2018Congress.pdf …

First presentation of initial data from Rubraca Phase 2 TRITON2 trial in advanced metastatic castrationresistant prostate cancer mCRPC First presentation of genomic profiling data based on tumo...

First presentation of initial data from Rubraca Phase 2 TRITON2 trial in advanced metastatic castrationresistant prostate cancer mCRPC First presentation of genomic profiling data based on tumor tissue ...

SummaryOxford Biodynamics Plc Oxford Biodynamics is a developer of biomarker discovery platform. The company concentrates on research in detection monitoring and prognosis of major diseases associated with aberrant gene expression such as oncology metaboli...

VolitionRx Limited NYSEVNRX CEO Cameron Reynolds speaks to Proactive at the MicroCap Conference in New York.Reynolds commented on recent preliminary data from a prospective study on Volition's Nu.Q assays to diagnose men with highgrade prostate cancer.He s...

Chez les hommes la prostate dtermine en quelque sorte la sant gnrale ou presque. Car les hommes qui souffrent de problmes urologiques tels que la dysfonction rectile les problmes urinaires et de vessie ou d&039;infertilit souffrent galement souvent de ...

SummaryThe Wistar Institute Wistar is a biomedical research institute that carries out medical research and training. The institute performs research in the areas of cancer infectious diseases immunology and vaccine development. It also conducts research o...

Read more...